BNTX BioNTech SE

BioNTech to Host Innovation Series R&D Day on November 14, 2024

BioNTech to Host Innovation Series R&D Day on November 14, 2024

MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.

On the day, BioNTech’s leadership team will provide an overview of the Company’s corporate strategy and clinical progress across its pipeline.

Investors, analysts and the interested public are invited to join the event online via this .

A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company’s website for one year following the call. The public may also access the presentation slides via the “Events & Presentations” page of the Investor Relations section of the Company’s website at . 

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.

For more information, please visit .

CONTACTS

Investor Relations

Michael Horowicz

Media Relations

Jasmina Alatovic

+49 (0)6131 9084 1513



 



EN
31/10/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioNTech SE

 PRESS RELEASE

BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur...

BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den mRNA-Krebsimmuntherapie-KandidatenBioNTech will BNT327/PM8002 als innovativen immunonkologischen („IO“) Schlüsselkandidat für die Kombinationsstrategie des Unternehmens entwickeln, der auf ein breites Spektrum von Krebsindikationen abzieltFortschritte in der Entwicklung von BNT327/PM8002 mit dem Beginn der globalen...

Ahmed Ben Salem
  • Ahmed Ben Salem

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/15/2024

Swiss-based Accelleron was formed from the spin-off of ABB’s highly profitable turbocharger division in 2022. We view the share as a promising investment on 1/ market leadership in an attractive niche, 2/ about ~40% ROCE, 3/ conversion of ~80% of EBITDA into cash, leading to fast deleveraging, and a solid base for shareholder remuneration (75% pay out), and 4/ strong long-term visibility linked to a ~75% service share, the bulk of which is recurring. Despite an already strong stock pe...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

BioNTech SE : R&D Day focused on oncology

>Three complementary approaches for five flagship molecules - - At yesterday's R&D day, BioNTech focused on its oncology portfolio structured around three complementary and potentially synergistic approaches: immunomodulators, mRNA vaccines and targeted therapy. On the product side, the company highlighted five flagship molecules: 1/ BNT327 (PDL1x VEGF bispecific), 2/ BNT122 autogenous cevumeran (individualised mRNA vaccine), 3/ FixVac (Off-the-shelf mRNA vaccin...

Damien Choplain ... (+2)
  • Damien Choplain
  • Martial Descoutures

BioNTech SE : R&D Day tourné vers l’oncologie

>Trois approches complémentaires pour 5 actifs flagships - Lors du R&D day qui s’est tenu hier, BioNTech a fait un focus sur son portefeuille en oncologie structuré autour de trois approches complémentaires et potentiellement synergiques : immunomodulateurs, vaccins à ARNm et thérapie ciblée. Coté produits, la société a mis en avant 5 molécules flagships : 1/ BNT327 (bispécifique PDL1x VEGF), 2/ BNT122 autogene cevumeran (Vaccin à ARNm personnalisé), 3/ FixVac (Vacc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch